Sandra Aleksic1, Ruth Eisenberg2, Effie Tsomos3, Sara Zahedpour Anaraki4, Emily Japp4, Laxmi Upadhyay4, Wenzhu Bi Mowrey2, Enver Akalin5, Joel Zonszein6. 1. Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: saleksic@montefiore.org. 2. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, United States. 3. Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai Medical Center, New York, NY, United States. 4. Department of Medicine, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, Bronx, NY, United States. 5. Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, Bronx, NY, United States. 6. Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, NY, United States.
Abstract
AIMS: Little is known about glycemic management, particularly with novel cardio-nephroprotecive agents, in underserved minority kidney transplant recipients with pre-transplant type 2 (T2DM) and posttransplantation diabetes mellitus (PTDM). We assessed glycemic management and outcomes in this high-risk population. METHODS: We reviewed records of patients who received kidney transplants between June 2012 and December 2014 at a single center. Hemoglobin A1c (HbA1c) and prescribed glucose-lowering medications were examined, and mortality was compared between T2DM, PTDM, and no diabetes (NoDM) patients. RESULTS: We followed 302 patient records (41.1% Hispanic, 41.1% non-Hispanic black) for a median (IQR) of 45.5 (37.0, 53.0) months post-transplant. Pre-transplant T2DM was present in 152 (50.3%), while 58 (19.2%) developed PTDM and 92 (30.4%) remained NoDM. At 1-year post-transplant, the average HbA1c was 8.1 ± 1.8% in T2DM and 6.6 ± 1.3% in PTDM. No glucose-lowering agents were prescribed in 3.4% of T2DM and 44.8% of PTDM. When treated, both received mostly insulin and metformin. Diabetes, HbA1c and insulin therapy were not independently associated with risk of mortality. CONCLUSIONS: Glycemic management was suboptimal and relied on older medications. Further studies are needed to assess longer-term outcomes of more rigorous glycemic management, and the value of novel cardio-nephroprotective agents in kidney transplant recipients.
AIMS: Little is known about glycemic management, particularly with novel cardio-nephroprotecive agents, in underserved minority kidney transplant recipients with pre-transplant type 2 (T2DM) and posttransplantation diabetes mellitus (PTDM). We assessed glycemic management and outcomes in this high-risk population. METHODS: We reviewed records of patients who received kidney transplants between June 2012 and December 2014 at a single center. Hemoglobin A1c (HbA1c) and prescribed glucose-lowering medications were examined, and mortality was compared between T2DM, PTDM, and no diabetes (NoDM) patients. RESULTS: We followed 302 patient records (41.1% Hispanic, 41.1% non-Hispanic black) for a median (IQR) of 45.5 (37.0, 53.0) months post-transplant. Pre-transplant T2DM was present in 152 (50.3%), while 58 (19.2%) developed PTDM and 92 (30.4%) remained NoDM. At 1-year post-transplant, the average HbA1c was 8.1 ± 1.8% in T2DM and 6.6 ± 1.3% in PTDM. No glucose-lowering agents were prescribed in 3.4% of T2DM and 44.8% of PTDM. When treated, both received mostly insulin and metformin. Diabetes, HbA1c and insulin therapy were not independently associated with risk of mortality. CONCLUSIONS: Glycemic management was suboptimal and relied on older medications. Further studies are needed to assess longer-term outcomes of more rigorous glycemic management, and the value of novel cardio-nephroprotective agents in kidney transplant recipients.
Authors: David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede Journal: Hypertension Date: 2016-07-11 Impact factor: 10.190
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: B I Freedman; B A Julian; S O Pastan; A K Israni; D Schladt; M D Gautreaux; V Hauptfeld; R A Bray; H M Gebel; A D Kirk; R S Gaston; J Rogers; A C Farney; G Orlando; R J Stratta; S Mohan; L Ma; C D Langefeld; P J Hicks; N D Palmer; P L Adams; A Palanisamy; A M Reeves-Daniel; J Divers Journal: Am J Transplant Date: 2015-03-24 Impact factor: 8.086
Authors: Esteban L Porrini; Jose M Díaz; Francisco Moreso; Patricia I Delgado Mallén; Irene Silva Torres; Meritxell Ibernon; Beatriz Bayés-Genís; Rocío Benitez-Ruiz; Ildefonso Lampreabe; Ricardo Lauzurrica; Jose M Osorio; Antonio Osuna; Rosa Domínguez-Rollán; Juan C Ruiz; Alejandro Jiménez-Sosa; Ana González-Rinne; Domingo Marrero-Miranda; Manuel Macía; Javier García; Armando Torres Journal: Nephrol Dial Transplant Date: 2015-11-03 Impact factor: 5.992
Authors: Mira T Keddis; Mireille El Ters; Emilio Rodrigo; Patrick Dean; Mariana Wohlfahrtova; Yogish C Kudva; Elizabeth C Lorenz; Fernando G Cosio Journal: Kidney Int Date: 2014-04-02 Impact factor: 10.612